Synairgen PLCShs News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.02.22	MÄRKTE EUROPA/Schwere Verluste - Ukraine-Krise verschärft sich weiter (Dow Jones)
21.02.22	MÄRKTE EUROPA/DAX kämpft mit wichtiger Unterstützung (Dow Jones)
21.02.22	MÄRKTE EUROPA/Börsen drehen ins Minus mit Peskow-Aussagen (Dow Jones)
30.09.21	Non-Executive Director Appointment (GlobeNewswire)
30.09.21	Interim results for the six months ended 30 June 2021 (GlobeNewswire)
24.05.21	Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants (GlobeNewswire)
12.05.21	Preliminary results for the year ended 31 December 2020 (GlobeNewswire)
30.04.21	Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial (GlobeNewswire)
15.02.21	Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients (GlobeNewswire)
25.01.21	Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients (GlobeNewswire)
20.01.21	Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta (GlobeNewswire)
13.01.21	Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients (GlobeNewswire)
18.12.20	COVID-19 Clinical Programme Update (GlobeNewswire)
20.07.20	Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V